All Congress Publications
Boehringer Ingelheim is committed to sharing knowledge with the healthcare community. Follow the links and find a variety of downloadable resources and articles with information related to Oncology.
41 - 45 of 45 results
Publications
Gathering our presentations, posters, abstracts, and publications, this educational resource offers materials across topics of interest in oncology. Explore the current topics below and revisit regularly to access the latest materials.
Infographic
Obrixtamig (BI 764532) in patients with relapsed/refractory DLL3-high expressing epNEC: trial in progress of the dose expansion part of the Phase II DAREON®-5 trial
Author(s): Pavel et al.
DAREON®-8: A Phase I trial of first-line obrixtamig plus chemotherapy and atezolizumab in extensive-stage small cell lung carcinoma (ES-SCLC)
Author(s): Peters et al.
DAREON®-9, a Phase Ib open-label dose escalation and dose confirmation study of obrixtamig (BI 764532) plus topotecan in patients with advanced small cell lung cancer: updated results
Author(s): Wermke et al.
An open-label, Phase Ib dose-expansion study to assess the efficacy of CD137 FAP agonist BI 765179 plus pembrolizumab as a first-line treatment in metastatic or incurable, PD-L1-positive HNSCC
Author(s): Shroff et al.
Systemic STING agonist BI 1703880 plus ezabenlimab in patients with advanced solid tumors: Initial results from a Phase Ia study
Author(s): Harrington et al.